基于Web of Science的利妥昔单抗治疗淋巴瘤文献计量分析  

Bibliometric analysis of rituximab in treating lymphoma literature based on Web of Science

作　　者：田晶辰[1] 赵志刚[1] 梅升辉[1] 韩容[1] TIAN Jing-chen;ZHAO Zhi-gang;MEI Sheng-hui;HAN Rong(Department of Pharmacy,Beijing Tiantan Hospital Affiliated to Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京天坛医院药学部,北京100050

出　　处：《临床药物治疗杂志》2018年第11期40-44,共5页Clinical Medication Journal

摘　　要：目的:了解利妥昔单抗治疗淋巴瘤的研究现状。方法:在Web of Science数据库中进行检索,以rituximab和lymphoma为主题词检索,利用数据库提供的出版年、研究方向、国家/地区、机构、作者和来源出版物等条件进行分析,并分析文献引用情况。结果:检索到13 163条文献,文章发表量与引文数逐年递增;hematology是该领域目前研究最多的方向;美国以占世界发表文章总量的36.50%名列第1位,中国则以5.56%名列第7位。排名前10位的机构均来自美国;中国研究机构中,中山大学、复旦大学和中国医学科学院文章发表最多。结论:美国在利妥昔单抗治疗淋巴瘤研究方面领先世界,欧洲和日本、中国等紧随其后,但中国与美国还存在较大的差距。Objective: To understand the current research status of rituximab in treating lymphoma. Methods: Web of Science based bibliometric analysis was carried out. The rituximab and lymphoma were chosen as terms during the literature searching in Web of Science citation database. The results were analyzed with regard to the number of articles, research sub-field, total citations, country/area, institutes, authors, journal of publication and so on The citation analysis was done automatically by the database. Results: A total of 13 163 literatures concerning rituximab and lymphoma were recorded in Web of Science. The total number of publications and citations keep increasing in this field. The hematology was the hottest and the most important sub-field in rituximab for lyrrphoma. The United States has the largest number of publications, which occupied 36.50% of the total amount of the published articles. China has occupied 5.56% of the total amount of the published articles. The United States accounts for the top ten institutions with the most article publication In China, Sun Yat-Sen University, Fudan University and Chinese Acadery of Medical Sciences were the top 3 institutions which have the highest number of publication. Conclusion: Rituximab for lymphoma is flourishing, with the United States being the global leader, followed by Western Europe, Japan and China, but there are a certain gap between China and the United States.

关 键 词：利妥昔单抗 淋巴瘤 文献计量分析 

分 类 号：R979.1[医药卫生—药品]